New clinical trial for GD3

Patients 12 years and older are needed for a clinical research study testing an orally administered treatment in Gaucher disease type 3.

This study will evaluate whether an investigational treatment, a substrate reduction therapy, is effective in treating patients 12 years and older with Gaucher disease type 3 while also further evaluating the study drug’s safety profile. This is a double blind, double dummy, randomised study which means that patients participating in the study will receive, either the study drug and placebo enzyme replacement therapy or enzyme replacement therapy and the placebo study drug, for a period of 52 weeks. Participants will not know if they received study drug or placebo during the initial 52 weeks of the study. All patients will receive the study drug during the extended treatment period of the study after completing the first 52 weeks. The extended treatment period will last a minimum of 52 weeks and a maximum of 130 weeks.

Forty patients will participate in the study and sites will include Argentina, Brazil, Canada, China, Egypt, France, Germany​, Japan, Hungary, Taiwan, Turkey, the United Kingdom, and the USA.

If you are interested, contact your treating physician who can assess your eligibility for the study.

Further information can be obtained on www.clinicaltrials.gov, using study identifier NCT05222906, or at www.clinicaltrialsregister.eu using study number EudraCT 2021-005402-10

× How can I help you?